Use of Medicines
Medicines aim to cure diseases, or at least relieve symptoms, to enable longer, healthier and more productive lives. Access to appropriate medicines, used sustainably, has substantial benefits for community health and related economic indicators.
OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?
16 January 2020
OHE Lunchtime Seminar with Alistair McGuire, 3rd February 2020. The seminar will present some preliminary thoughts on the promises offered by personalised medicine that it will…
Making Outcome-Based Payment a Reality in the NHS
2 January 2019
This report explores the feasibility of introducing one type of flexible payment mechanism – outcome-based payment (OBP) – for cancer medicines into the NHS in England. OBP could help to accelerate patient access to some new medicines and ensure close monitoring of real-world patient benefit.
Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS
29 August 2018
OHE Consulting produces a report on Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS.
Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? A Summary of a Symposium held at HTAi Rome 2017
31 October 2017
OHE has just published a new briefing entitled ‘Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?’
Opportunities for Utilising ‘Real World Data’ in South Korea
20 October 2017
OHE publishes a report assessing the capacity in South Korea for the collection and use of real-world data in health care.
Policy Options for Formulary Development in Middle-income Countries
1 January 2017
PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion. This report presents a framework…
Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study
1 January 2017
PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion. In a previous…
How to Manage Data Governance in an Era of Real World Evidence (RWE): Working Towards a Set of International Standards
24 November 2015
A new OHE Consulting Report assesses information governance arrangements for real-world data in eight countries, and makes recommendations towards an ideal governance framework.
Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
31 March 2015
A new OHE Consulting Report considers the data capabilities in the UK for monitoring medicine use according to indication using real world data.